Zurcher Kantonalbank Zurich Cantonalbank Sells 360,700 Shares of Bruker Co. (NASDAQ:BRKR)

Zurcher Kantonalbank Zurich Cantonalbank lessened its holdings in shares of Bruker Co. (NASDAQ:BRKR - Free Report) by 87.9% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 49,534 shares of the medical research company's stock after selling 360,700 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Bruker were worth $2,904,000 at the end of the most recent quarter.

A number of other large investors have also bought and sold shares of BRKR. FMR LLC boosted its holdings in shares of Bruker by 21.4% in the third quarter. FMR LLC now owns 14,306,122 shares of the medical research company's stock valued at $987,981,000 after buying an additional 2,521,904 shares during the period. State Street Corp lifted its position in Bruker by 9.6% in the 3rd quarter. State Street Corp now owns 3,627,300 shares of the medical research company's stock valued at $250,501,000 after acquiring an additional 318,808 shares in the last quarter. RTW Investments LP lifted its position in Bruker by 1.1% in the 3rd quarter. RTW Investments LP now owns 3,481,119 shares of the medical research company's stock valued at $240,406,000 after acquiring an additional 37,024 shares in the last quarter. Geode Capital Management LLC boosted its stake in Bruker by 10.8% in the 3rd quarter. Geode Capital Management LLC now owns 1,993,468 shares of the medical research company's stock worth $137,702,000 after purchasing an additional 193,580 shares during the period. Finally, Vaughan Nelson Investment Management L.P. increased its holdings in Bruker by 140.3% during the 4th quarter. Vaughan Nelson Investment Management L.P. now owns 1,141,762 shares of the medical research company's stock worth $66,930,000 after purchasing an additional 666,617 shares in the last quarter. 79.52% of the stock is owned by institutional investors.

Remove Ads

Bruker Stock Performance

NASDAQ BRKR traded down $0.53 during trading on Wednesday, reaching $46.61. 1,392,881 shares of the company's stock were exchanged, compared to its average volume of 1,288,808. The company has a debt-to-equity ratio of 1.15, a current ratio of 1.60 and a quick ratio of 0.77. The stock has a market capitalization of $7.07 billion, a P/E ratio of 61.34, a PEG ratio of 2.16 and a beta of 1.18. Bruker Co. has a fifty-two week low of $44.11 and a fifty-two week high of $94.86. The business has a 50 day moving average price of $53.10 and a 200-day moving average price of $58.07.

Bruker (NASDAQ:BRKR - Get Free Report) last released its quarterly earnings data on Thursday, February 13th. The medical research company reported $0.76 EPS for the quarter, topping analysts' consensus estimates of $0.75 by $0.01. Bruker had a net margin of 3.36% and a return on equity of 21.01%. Sell-side analysts forecast that Bruker Co. will post 2.69 earnings per share for the current fiscal year.

Bruker Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 28th. Shareholders of record on Monday, March 17th will be given a dividend of $0.05 per share. The ex-dividend date of this dividend is Monday, March 17th. This represents a $0.20 annualized dividend and a yield of 0.43%. Bruker's dividend payout ratio (DPR) is presently 26.32%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on BRKR. Bank of America upped their price objective on Bruker from $78.00 to $80.00 and gave the stock a "buy" rating in a research report on Friday, December 13th. The Goldman Sachs Group raised shares of Bruker from a "sell" rating to a "neutral" rating and set a $60.00 price target for the company in a research note on Thursday, December 5th. Stifel Nicolaus cut their price objective on shares of Bruker from $70.00 to $57.00 and set a "hold" rating on the stock in a research report on Friday, February 14th. Barclays reduced their target price on shares of Bruker from $69.00 to $65.00 and set an "overweight" rating for the company in a report on Monday, February 10th. Finally, UBS Group assumed coverage on shares of Bruker in a research note on Tuesday, December 10th. They issued a "neutral" rating and a $66.00 price target on the stock. Six equities research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $70.50.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.